1800 244 735

Helpline (02) 9874 9777

Welcome to HDBuzz

HDBuzz is now live! Your source for Huntington’s disease research news, in plain language, written by scientists, for the global HD community. Reliable, impartial and free to share, HDBuzz will bring you solid reasons to have hope, by explaining latest news from the worldwide effort to find effective treatments for HD.

Welcome to HDBuzz

It’s our great pleasure to announce the launch of HDBuzz, a new Internet platform for the latest news about Huntington’s disease research in plain language, written by scientists who work on HD. HDBuzz is dedicated to the people who need it most – those affected by HD and their family and friends.

Huntington’s disease research news

HDBuzz will give the global HD community free access to reliable, unbiased articles that reveal and explain the amazing, cutting-edge science that’s happening in labs and clinics around the world. You can expect a story or two a week, focused on particularly exciting developments in both clinical and basic research. Also look for in-depth coverage of HD scientific conferences and other events of interest to the community.

In plain language

HDBuzz will give you access to cutting-edge science, because we believe that all scientific progress can be explained in a way that allows non-scientists to understand it – in fact, we believe that no scientific work is complete until it’s been understood by the people it concerns.

HDBuzz is an experiment, and we need to know from you how we’re doing. If an article didn’t make sense, click the ‘Didn’t understand’ button and tell us how we can improve our content. If you like an article, click the ‘enjoyed’ button to let us know.

On the hdbuzz.net site, glossary pop-ups will explain any technical terms we have to use.

Written by scientists

HDBuzz writers and editors are qualified scientists and clinicians involved in the global effort to find treatments for HD. To remain independent, writers never report on their own research, and every writer completes a ‘conflicts of interest’ statement for each article.

You can find out about the HDBuzz team via the ‘About’ section.

For the global HD community

HDBuzz is the result of an exciting collaboration between many people all over the world, and we want our content to reach as far as possible. HD knows no cultural boundaries, and neither should access to information about HD.

HDBuzz is funded by a unique consortium of HD patient organizations. Our major supporters are the Huntington’s Disease Society of America, Huntington’s Disease Association of England and Wales and the Huntington Society of Canada and we hope to welcome more global HD organizations to the consortium during 2011.

We aim to make all HDBuzz content available in as many languages as possible. We are launching in English and Spanish, and hope to add French, German and Dutch in the very near future.

Where to find us

You’ll be able to access all HDBuzz content via our web site, hdbuzz.net, and articles will also be syndicated to the HD community sites you already use – like hdsa.org, hda.org.uk and huntingtonsociety.ca where we hope they’ll provoke lively, informed debate.

HDBuzz has news feeds to the major social networking sites so you can follow HDBuzzFeed on Twitter, Facebook or Google Buzz. You can also get updates by email.

And if you have a web page or blog, you can freely use HDBuzz content automatically via RSS or reproduce specific articles you like. See our sharing page, within the about section, for full details.

Hope through knowledge

It is a very exciting time for HD research – in the coming months and years, we expect real progress towards effective treatments for this disease we’re all united to fight.

We look forward to bringing that excitement to you, and giving you solid reasons to have real hope, through HDBuzz.

Share on facebook
Share on twitter
Share on pinterest
Share on email

Latest Research Articles

Updates from the EHDN Meeting 2021

Published date: 28 October, 2021

Last month, the Huntington’s disease (HD) research community, patients and other stakeholders met online at the European Huntington’s disease network (EHDN) conference. Despite the ongoing global pandemic, there is a tremendous amount of work underway in labs and clinics around the world as researchers continue to better understand HD and how we might best treat ... Read more

Real talk: Q&A with Roche about GENERATION-HD1

Published date: 28 September, 2021

At the end of day 1 of the European Huntington’s Disease Network (EHDN) conference, the HDBuzz team (minus one) sat down for a zoom chat with the team at Roche to have a frank, candid discussion about the recent halting of GENERATION-HD1, the Phase 3 clinical trial that was testing the ability of the antisense ... Read more

Another tool in the box: Creation of a molecular “dimmer switch” advances gene editing

Published date: 30 August, 2021

A team of scientists recently created an innovative genetic system where a drug taken by mouth could be used to control the action of a gene editor, like those used in CRISPR systems. This has useful applications for research studies in cells and animals, and perhaps most importantly, could lead to improvements in the safety ... Read more

Unpacking recent gene therapy press

Published date: 16 August, 2021

A recent announcement from Voyager Therapeutics outlined a shift in the company’s strategy towards an exciting new technology for gene therapy delivery. Unfortunately this also means that in the short term, they have dropped previous plans to test an HD gene therapy in people with HD. While this news is disappointing, the decision to embrace ... Read more

Does blood hold the key to testing treatments earlier in HD patients?

Published date: 4 August, 2021

Researchers at Johns Hopkins led by Wenzhen Duan have developed a non-invasive way to track progression of Huntington’s disease (HD) which could be used before patients even start showing symptoms. Using a type of brain scan called an MRI, the researchers have shown that in mouse models of HD they can accurately measure the amount ... Read more

A first for CRISPR gene editing could have wider applications for human disease

Published date: 21 July, 2021

A recent clinical trial successfully tested the safety of CRISPR gene editing to reduce the amount of a toxic protein in patients with Familial Transthyretic (TTR) Amyloidosis. Although this study is unrelated to Huntington’s disease, it’s a first for gene editing, and the results could have implications for HD and other brain disorders. CRISPR-Cas9 Clustered ... Read more